Literature DB >> 649349

Observations on immunization against cutaneous leishmaniasis in Israel.

Z Koufman, N Egoz, C L Greenblatt, E Handman, B Montilio, Z Even-Paz.   

Abstract

Trials of immunization against Leishmania tropica were initiated in the Israel Defense Forces in 1968. The rate of takes has declined gradually over the years. In 1975, 425 soldiers were inoculated with the same strain of L. tropica as that used since 1968; they were examined at three- and six-month intervals after the inoculation, with 291 soldiers undergoing at least one follow-up examination. Only 13.7% developed lesions at the inoculation site, usually between three and six months after the inoculation. Leishmanin tests were performed in 220 soldiers and there were positive reactions in 19.5%. There was a fair correlation between the development of clinical lesions and positive leishmanin tests. A positive leishmanin test, or a typical lesion, or both, was seen in 21.3% of the inoculated soldiers. L. tropica tends to lose its virulence after prolonged storage and multiple passages. A new strain isolated a few months before this trial was used to inoculate 50 soldiers, 31 of whom were followed up. All 31 developed typical lesions at the site of inoculation, most of them within two to four weeks following the inoculation.

Entities:  

Mesh:

Year:  1978        PMID: 649349

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  3 in total

1.  Protection of guinea pigs against cutaneous leishmaniasis by combined infection and chemotherapy.

Authors:  J El-On; A Witztum; L F Schnur
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

2.  Immunogenicity of soluble and particulate antigens from Leishmania donovani: effect of glucan as an adjuvant.

Authors:  J A Cook; T W Holbrook
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

Review 3.  Live vaccination tactics: possible approaches for controlling visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahareh Taheri; Sima Rafati
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.